Who we are.

Third-largest global player in the €190 billion OTC & VMS market, delivering compelling growth through 100 beloved brands serving 500 million consumers worldwide1. Backed by CD&R and driven by our mission — “Health. In your hands” — we are unlocking long-term value creation, empowering consumers to take charge of their health.

Key figures.

#3 globally

leading OTC & VMS player2.

 

€5bn

revenues in 20243.

11.000+

Employees.​

 

90+

Nationalities.

​~100

Brands portfolio​.

38

countries with direct operations.​

 

~110

countries served indirectly.

​13

World-class manufacturing sites​.

​4

Specialized science & innovation centers​.

Press Release.

Opella reprices its two term loan B facilities.
 

Discover.

Financial calendar.

Next financial communication: FY2025 expected to be released end of Q1 2026.

B Corp Certification.

As of April 2025, Opella is proud to be the first global consumer healthcare company to achieve B CorpTM Certification, meeting the rigorous social, environmental, and governance standards set by B Lab.​

Read more.

Reach out.

Have a question or simply want to know more?
You can contact our IR team.

Drop us a line.